Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
NCT01346930
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG:
Macitentan
Sponsor
Actelion